Golimumab: clinical update on its use for ulcerative colitis.
Drugs Today (Barc)
; 51(3): 171-84, 2015 Mar.
Article
en En
| MEDLINE
| ID: mdl-25876561
Monoclonal antibodies directed against tumor necrosis factor alpha (anti-TNF-α agents) have dramatically changed the therapeutical approach to inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. A new anti-TNF drug, golimumab, has recently been approved for patients with moderate to severe ulcerative colitis. Its efficacy has been demonstrated by preclinical and clinical studies and the drug showed an efficacy and safety profile in line with the other anti-TNF agents, such as infliximab and adalimumab. This review gives an overview on golimumab in the treatment of moderate to severe ulcerative colitis.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Colitis Ulcerosa
/
Antiinflamatorios no Esteroideos
/
Factor de Necrosis Tumoral alfa
/
Anticuerpos Monoclonales
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Drugs Today (Barc)
Asunto de la revista:
MEDICINA OCUPACIONAL
/
SAUDE AMBIENTAL
Año:
2015
Tipo del documento:
Article
País de afiliación:
Italia
Pais de publicación:
España